About Us
Since its foundation in 1964, Hänseler AG has been an innovative Swiss manufacturing and trading company in the pharmaceutical and healthcare industry, based in Herisau.
Hänseler AG is successful on three levels. The company's three mainstays are trading and processing of raw materials, manufacturing and distribution of OTC products, and production and packaging on behalf of partner companies.
As the Swiss market leader for pharmaceutical raw materials, we carry over 3‘000 raw materials and renowned brands such as Gly-Coramine®, Original Bach®-Blüten/RESCUE®, OLBAS® and the Kidney and Bladder Dragées S in the range. Most of the 1’800 Swiss pharmacies and 400 drugstores as well as numerous industrial/export customers use the competence and quality made in Herisau.
Most of the 1‘800 pharmacies and 400 drugstores in Switzerland are Hänseler customers and, like industrial and export customers, are served competently and with commitment by our total of 135 employees.
Our core competencies
Raw materials
Tested raw materials for health and wellness. As a GMP-certified company, we claim that our suppliers fully comply with pharmaceutical guidelines.More about raw materials
Contract manufacturing
You have special requirements and need support in your project? We support you with state-of-the-art technologies, a high level of expertise and qualified employees.More about contract manufacturing
Products & Brands
The "bestsellers" of our OTC products meet the high demands of customers in the Swiss specialty trade, and we guarantee the desired efficacy and tolerability.Products & Brands
Growth over decades
The history of Hänseler AG begins in 1964 with Edwin Hänseler, who built up a flourishing trade by manufacturing pharmaceutical preparations. At the turn of the millennium, the company was expanded with a large-scale new building and extension. Today, Hänseler AG employs 135 people, who personally handle around 4,200 customer contacts per year and around 600 deliveries per day. Further expansion projects at the Herisau site are being planned.
1964
Edwin Hänseler starts manufacturing and trading pharmaceutical products
1975
Entry in the commercial register as Hänseler AG in Herisau
2004
Acquisition of the majority of shares by Steinegg Foundation, Herisau
2006
Extensive new construction and conversion work
2009
Pioneer in the development of GID intermediates (raw materials)
2010
Acquisition of the Alcacyl® and Gly-Coramin® brands
2013
New corporate design
2015
Entry into the Asian market with Planox®
2015
Building business model with medical cannabis (THC)
2016
Entry into the retail market in Switzerland
2018
National THMP approvals in Spain, Norway and Sweden
2020
Brand takeover of Kelosoft®, launch of Hänseler Forte and Hänseler Achillea. Biocide approval and launch of Hänseler Desinfect range.
2021
Introduction kidney and bladder dragéess in Norway
2022
FDA audit successfully passed
Vision and Mission
We are a manufacturing Swiss pharmaceutical company with the highest quality standards and innovative solutions. We are the first address for a full range of pharmaceutical raw materials in customer-oriented quantities with a qualified «supply chain» and a specialist for selected finished medicinal products with a focus on women's health. We see ourselves as an expert für GMP contract manufacturing of small and medium lot sizes and are thanks to flexible and modern production processes
active.
We enthusiastically exceed the wishes of our customers.
Our contribution to achieving the global sustainability goals
«Sustainability» is an important topic for all of us. Back in 2015, the United Nations (UN) defined the 17 Sustainable Development Goals (SDGs) and their 169 sub-goals.These sustainability goals are to be achieved globally and by all UN member states by 2030. Thus, all states are equally called upon to jointly solve the pressing challenges of the world and minimize the negative impact on our planet, so that we offer our customers, partners and employees and society an added value. Hänseler AG is a participant of the Swiss Tripple Impact Program and focuses on the following goals:
SDG 3:
Provide a healthy life for all people of all ages and promote their well-being.
All people should be guaranteed access to quality health services and medicines. This sustainability goal also includes the fight against non-communicable diseases (e.g. diabetes mellitus) and the prevention of traffic accidents, as well as the reduction of substance abuse.
SDG 5:
Achieve gender equality and empower all women and girls.
Goal 5 advocates for equal opportunities between men and women in economic development; calls for the elimination of all forms of violence against women and girls, including the abolition of early and forced marriages; and promotes equal participation at all levels.
SDG 9:
Build resilient infrastructure, promote broad-based and sustainable industrialization, and support innovation.
To make infrastructures and industries sustainable, Goal 9 states that by 2030, resources will be used more efficiently. Cleaner, more environmentally sound technologies and industrial processes will be promoted, and access to financial services for SMEs and other businesses will be ensured.
SDG 12:
Provide for sustainable consumption and production patterns.
Environmentally friendly handling of chemicals and other waste is to be achieved by 2030. Waste is to be significantly reduced through recycling. Companies that commit to Sustainability Goal 12 should practice sustainable corporate governance.
Supply and values
Pharmaceutical raw materials
We guarantee a wide range of herbal and chemical raw materials in pharmaceutical quality and consumer-friendly packaging.
Finished Products
We are consistently expanding our range of finished products with the aim of being the leading provider of OTC therapeutics in the field of women's health.
Contract manufacturing
We produce to the highest pharmaceutical GMP quality, specializing in liquid, semi-solid and solid forms and making even the impossible possible.
Customers
We meet customer requirements quickly and reliably. In particular, pharmacies, drugstores, hospitals, doctors and industry at home and abroad benefit from our specific "know how".
Service provision
We are a Swiss company with high quality standards. Our focus is on the home market and the growing foreign business.
Company and ownership
We are committed to Switzerland as a business location and in particular to Appenzellerland.Our shareholder base, ensures the continuous development of the company.
Worth knowing at a glance
Hänseler AG is an independent, financially autonomous pharmaceutical company. The main shareholder is the Steinegg Foundation, which is domiciled in Herisau. This foundation is committed to maintaining a healthy economic structure in the region.The investments made in personnel and infrastructure in recent years and the expansion of our market position have created key conditions for the healthy and sustainable development of our company.